Gilead Vosevi’s (Sofosbuvir/Velpatasvir/Voxilaprevir) price at $24,920 per bottle

Investment Commentary

Gilead gets its go-ahead for blockbuster hopeful Vosevi, but will 12-week dosing give it trouble?
by Carly Helfand |
Jul 19, 2017 11:15am 

Gilead has set Vosevi’s price at $24,920 per bottle, putting it “at parity” with Epclusa at $74,760 for the 12-week course, Porges wrote in a note to clients. “Effectively Gilead is giving the third component of Vosevi free of charge to maintain the price point of their 12-week treatment course,” he said, noting that “ given this label and position in the treatment hierarchy, Gilead could have priced Vosevi higher and probably not lost significant share.”

Continue reading .. http://www.fiercepharma.com/pharma/gilead-wins-blockbuster-approval-for-hep-c-trio-vosevi-but-will-12-week-dosing-give-it

Investment Commentary
How AbbVie Could Hammer Gilead's Hepatitis C Franchise 

ALLISON GATLIN

7/19/2017

Meanwhile, AbbVie's combination of glecaprevir and pibrentasvir looks likely to gain approval as an eight-week regimen in all genotypes of hepatitis C and in patients who've never undergone treatment. Gilead's Harvoni is approved as an eight-week regimen, but only in one subset of patients.Gilead is pricing its triple-pill, which will be branded as Vosevi, at $24,920 per bottle. At one bottle per month, that runs up to a 12-week price of about $75,000. That is less costly than Gilead's Harvoni and Sovaldi, but more expensive than Zepatier

 Continue reading.....

Recommended Reading
Gilead's VoseviTM (Sofosbuvir/Velpatasvir/Voxilaprevir) FDA Approved for Re-Treatment of Adults with HCV